Semenzato Laura, Botton Jérémie, Drouin Jérôme, Cuenot François, Dray-Spira Rosemary, Weill Alain, Zureik Mahmoud
EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance.
University Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, 78180, Montigny le Bretonneux, France.
Lancet Reg Health Eur. 2021 Sep;8:100158. doi: 10.1016/j.lanepe.2021.100158. Epub 2021 Jul 16.
From the beginning of the COVID-19 pandemic, age (most importantly), male gender and various comorbidities were found to be associated with severe forms of COVID-19. However, there was little information provided for an entire country such as France, which was severely affected throughout the epidemic.
In France, the SNDS, comprising all health insurance reimbursements and benefits, and the PMSI, comprising hospital data, can be used to estimate the risk associated with about fifty diseases or health conditions for hospitalization primarily related to COVID-19 and COVID-19-related deaths. A cohort was constituted comprising all people alive on February 15, 2020. Data were censored at 15 June 2020 for COVID-19-related hospitalization and at 15 July 2020 for death for patients still hospitalized for COVID-19 on 15 June 2020. Cox proportional hazards models were used to estimate hazard ratios (HR) for the associations between each comorbidity (n=47) and the risk of COVID-19-related hospitalization or death. These associations were determined with adjustment for age and gender, and then in models including all variables (adjusted hazard ratios [aHR]).
In a population of 66,050,090 people, 87,809 people (134 per 100,000) were hospitalized for COVID-19 between February 15, 2020 and June 15, 2020 and a subgroup of 15,661 people (24 per 100,000) died in hospital.A much higher risk was observed with increasing age, reaching a risk of hospitalization for COVID-19 more than five fold higher and a risk of COVID-19-related in-hospital mortality more than 100-fold higher in people aged 85 years and older (absolute risks of 750 and 268 per 100,000, respectively) compared to people aged 40 to 44 years.Men were at higher risk of COVID-19-related hospitalization aHR 1.38 [1.36-1.40]) and COVID-19-related in-hospital mortality (aHR 2.08 [2.01-2.16]) compared to women. Positive associations between social deprivation index and risk of COVID-19 were also observed. Almost all chronic health conditions were positively associated with an increased risk of COVID-19-related hospitalization and in-hospital mortality, with the exception of dyslipidaemia, which was negatively associated. The strongest associations for both COVID-19-related hospitalization and in-hospital mortality were observed in people with Down syndrome (7.0 [6.1-8.1] and 22.9 [17.1-30.7], respectively), mental retardation (3.8 [3.5-4.2] and 7.3 [6.1-8.8], respectively), kidney transplantation (4.6 [4.2-5.0] and 7.1 [6.0-8.4], respectively), lung transplantation (3.5 [2.4-5.3] and 6.2 [2.8-14.0], respectively) end-stage renal disease on dialysis (4.2 [3.9-4.4] and 4.7 [4.2-5.2], respectively) and active lung cancer (2.6 [2.4-2.8] and 4.0 [3.5-4.6], respectively).
This national cohort study confirms the associations with most diseases and health conditions in France and provides data on less frequent health conditions, which could be useful particularly to target priority populations during present and future vaccination campaigns.
None.
自新冠疫情开始以来,人们发现年龄(最为重要)、男性性别以及各种合并症与新冠重症形式有关。然而,对于像法国这样在整个疫情期间都受到严重影响的国家,所提供的相关信息却很少。
在法国,涵盖所有医疗保险报销和福利的全国疾病数据系统(SNDS)以及包含医院数据的患者医疗信息系统(PMSI),可用于估算与约五十种疾病或健康状况相关的风险,这些疾病或健康状况主要与新冠相关住院治疗及新冠相关死亡有关。研究构建了一个队列,纳入了2020年2月15日仍在世的所有人。对于新冠相关住院治疗的数据,截止日期为2020年6月15日;对于2020年6月15日仍因新冠住院的患者,死亡数据截止日期为2020年7月15日。采用Cox比例风险模型来估算每种合并症(共47种)与新冠相关住院治疗或死亡风险之间的风险比(HR)。这些关联在对年龄和性别进行调整后确定,然后在包含所有变量的模型中进行分析(调整后风险比 [aHR])。
在66050090人的总体人群中,2020年2月15日至2020年6月15日期间,有87809人(每10万人中有134人)因新冠住院,其中15661人(每10万人中有24人)在医院死亡。随着年龄增长,风险显著升高,85岁及以上人群因新冠住院的风险比40至44岁人群高出五倍多,因新冠相关住院死亡率高出100倍多(每10万人的绝对风险分别为750和268)。与女性相比,男性因新冠相关住院的风险更高(调整后风险比1.38 [1.36 - 1.40]),因新冠相关住院死亡率也更高(调整后风险比2.08 [2.01 - 2.16])。社会剥夺指数与新冠风险之间也存在正相关关系。几乎所有慢性健康状况都与新冠相关住院和住院死亡率增加呈正相关,但血脂异常呈负相关。唐氏综合征患者(分别为7.0 [6.1 - 8.1] 和22.9 [17.1 - 30.7])、智力障碍患者(分别为3.8 [3.5 - 4.2] 和7.3 [6.1 - 8.8])、肾移植患者(分别为4.6 [4.2 - 5.0] 和7.1 [6.0 - 8.4])、肺移植患者(分别为3.5 [2.4 - 5.3] 和6.2 [2.8 - 14.0])、接受透析的终末期肾病患者(分别为4.2 [3.9 - 4.4] 和4.7 [4.2 - 5.2])以及活动性肺癌患者(分别为2.6 [2.4 - 2.8] 和4.0 [3.5 - 4.6])的新冠相关住院和住院死亡率的关联最为强烈。
这项全国性队列研究证实了法国大多数疾病和健康状况与新冠之间的关联,并提供了关于较少见健康状况的数据,这对于当前和未来疫苗接种活动中确定重点人群可能特别有用。
无。